Catheter Advancement System Offers Remote Control of Proprietary Deflectable Sheath during Cardiac Ablation Procedures
ST. LOUIS, July 26, 2016 (GLOBE NEWSWIRE) -- Stereotaxis, Inc. (NASDAQ:STXS), a global leader in innovative technologies for the treatment of cardiac arrhythmias, today announced the market release of its second generation V-CAS Deflect™ catheter advancement system in Europe. The V-CAS Deflect catheter advancement system is designed to remotely control a proprietary robotic deflectable sheath during a cardiac ablation procedure with the Stereotaxis Niobe® remote magnetic navigation system. The deflectable sheath provides improved support, stability and maneuverability of the magnetic ablation catheter during therapy delivery.
“We have made considerable advancements to our V-CAS Deflect system design with this latest iteration and are very pleased to bring physicians even greater access and versatility in magnetic catheter navigation within all four chambers of the heart,” said William C. Mills, Stereotaxis Chief Executive Officer. “By remotely controlling both the magnetic catheter body and deflectable steering sheath, the V-CAS Deflect system, in combination with the Niobe system, enables safer, more efficient single-operator procedures for complex arrhythmias and further progresses our vision of a fully remote ablation environment.”
Part of the Stereotaxis Vdrive® robotic navigation system portfolio, the V-CAS Deflect catheter advancement system incorporates a disposable, deflectable sheath capable of 210-degree deflection at the distal end. Integrated electrodes on the sheath are optimized for display on a mapping system, enabling standard sheath techniques and adjustments to be visualized and performed from a control room rather than from within the radiation field of the procedure room. The new version includes features to improve performance in smaller heart chambers, provide better navigation through complex anatomy, and enhance visualization on 3D mapping systems. The use of the V-CAS Deflect system negates the need for any other type of deflectable sheath when conducting magnetic procedures.
The enhanced V-CAS Deflect system has already been successfully utilized in procedures performed at St. Olav’s Hospital in Norway and Centre Hospitalier Princess Grace in Monaco.
Stereotaxis is a healthcare technology and innovation leader in the development of robotic cardiology instrument navigation systems designed to enhance the treatment of arrhythmias and coronary disease, as well as information management solutions for the interventional lab. Over 100 issued patents support the Stereotaxis platform, which helps physicians around the world provide unsurpassed patient care with robotic precision and safety, improved lab efficiency and productivity, and enhanced integration of procedural information. Stereotaxis' core Epoch® Solution includes the Niobe® magnetic navigation system, the Odyssey® portfolio of lab optimization, networking and patient information management solutions, and the Vdrive® robotic navigation system and consumables.
The core components of Stereotaxis’ systems have received regulatory clearance in the United States, European Union, Canada, China, Japan, and elsewhere. The V-Sono™ ICE catheter manipulator, V-Loop™ variable loop catheter manipulator, and V-CAS™ catheter advancement system have received clearance in the United States, Canada, and the European Union. The V-CAS Deflect™ catheter advancement system is available for use in the European Union. For more information, please visit www.stereotaxis.com.
This press release includes statements that may constitute "forward-looking" statements, usually containing the words "believe”, "estimate”, "project”, "expect" or similar expressions. Forward-looking statements inherently involve risks and uncertainties that could cause actual results to differ materially from the forward-looking statements. Factors that would cause or contribute to such differences include, but are not limited to, the Company's ability to raise additional capital on a timely basis and on terms that are acceptable, its continued listing on the NASDAQ Capital Market, its ability to continue to manage expenses and cash burn rate at sustainable levels, its ability to continue to work with lenders to extend, repay or refinance indebtedness on acceptable terms, continued acceptance of the Company's products in the marketplace, the effect of global economic conditions on the ability and willingness of customers to purchase its systems and the timing of such purchases, competitive factors, changes resulting from the recently enacted healthcare reform in the United States, including changes in government reimbursement procedures, dependence upon third-party vendors, timing of regulatory approvals, and other risks discussed in the Company's periodic and other filings with the Securities and Exchange Commission. By making these forward-looking statements, the Company undertakes no obligation to update these statements for revisions or changes after the date of this release. There can be no assurance that the Company will recognize revenue related to its purchase orders and other commitments in any particular period or at all because some of these purchase orders and other commitments are subject to contingencies that are outside of the Company's control. In addition, these orders and commitments may be revised, modified, delayed or canceled, either by their express terms, as a result of negotiations, or by overall project changes or delays.
Martin C. Stammer
Chief Financial Officer
Todd Kehrli / Jim Byers
MKR Group, Inc.